“Breakthrough” Means Breaking Down Bureaucracy
This article was originally published in RPM Report
Executive Summary
FDA’s Richard Pazdur has the oncology review team at FDA out on the cutting edge of “Breakthrough” reviews. He sees the key elements of making breakthrough work as cutting through layers of traditional processes and setting faster pathways for subsequent drugs.